Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $120
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $102 to $120.
Oppenheimer Downgrades AtriCure to Perform
Oppenheimer analyst Suraj Kalia downgrades AtriCure (NASDAQ:ATRC) from Outperform to Perform.
SVB Leerink Maintains Outperform on AtriCure, Raises Price Target to $100
SVB Leerink analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Outperform and raises the price target from $95 to $100.
Needham Maintains Buy on AtriCure, Lowers Price Target to $90
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $91 to $90.
AtriCure Q2 EPS $(0.30) Beats $(0.33) Estimate, Sales $71.38M Beat $61.07M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 21.05 percent increase over losses of $(0.38) per share from the same
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Stocks That Hit 52-Week Highs On Friday
On Friday morning, 154 companies achieved new highs for the year.
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 115 companies hit new 52-week highs.